Key facts
- Mission Bio’s last known valuation is $300.0M (May 2022).
- It has raised $212.1M across 2 recorded rounds; the latest was Early Stage VC ($28.4M) in Jun 2018.
- Notable investors include Alumni Ventures, StartX (US), Keiretsu Forum, Evolution VC Partners, Sand Hill Angels — 41 tracked in total.
- Mission Bio has filed 2 Form Ds with the SEC since 2017, most recently Jul 2018 ($28.4M sold to 32 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 41 names
- ·Watchlist + deal alerts for Mission Bio
Funding rounds
2 roundsAbout Mission Bio
Developer of a precision genomics platform designed to provide single-cell targeted DNA sequencing at single-base resolution. The company's platform integrates targeted DNA sequencing with protein expression profiling at single-cell resolution, supports detection of single nucleotide and copy number variations, enables characterization of clonal heterogeneity and gene edits, and includes customizable panels and assay development services, enabling researchers and clinicians in oncology and cell therapy to uncover genetic diversity, improve therapeutic targeting, and accelerate biomarker discovery.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2011
- Employees
- 76
- Website
- missionbio.com/
- Ownership
- Privately Held (backing)
Mission Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mission Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mission Bio in its N-PORT filings yet. We sweep new filings monthly.